Holen Sie sich die Stockscreener-App
343.60
8.39%
26.60
Vorhandelsmarkt:
343.60
Schlusskurs vom Vortag:
$317.00
Offen:
$325.95
24-Stunden-Volumen:
703.32K
Relative Volume:
1.51
Marktkapitalisierung:
$9.57B
Einnahmen:
$7.46M
Nettoeinkommen (Verlust:
$-303.27M
KGV:
-25.51
EPS:
-13.4668
Netto-Cashflow:
$-249.12M
1W Leistung:
+12.03%
1M Leistung:
+16.89%
6M Leistung:
+554.23%
1J Leistung:
+1,055%
1-Tages-Spanne:
$325.95
$352.78
1-Wochen-Bereich:
$311.01
$352.78
52-Wochen-Spanne:
$28.79
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
343.60 | 8.80B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia
Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK
Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga
Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com Australia
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application - marketscreener.com
Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - Bitget
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today
7 million Americans with essential tremor see a first positive Phase 3 program - Stock Titan
Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target - marketscreener.com
Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com
A Look At Praxis Precision Medicines (PRAX) Valuation After Positive Elsunersen Seizure Reduction Data - simplywall.st
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
PRAX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Wolfe Research Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $500 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $500 to $1,245 - Moomoo
Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights
H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com
HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus
Praxis Precision Medicines Announces Positive EMBRAVE Part A Trial Results for Elsunersen in Pediatric SCN2A Epileptic Encephalopathy - Minichart
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine - Investing.com Australia
Praxis reports positive elsunersen trial in pediatric epilepsies - TipRanks
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine By Investing.com - Investing.com South Africa
Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine - TradingView — Track All Markets
Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PR - GuruFocus
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com
BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - marketbeat.com
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In TrialPraxis Precision Medicine (NAS - Benzinga
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - Investing News Network
Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy - TradingView — Track All Markets
In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - marketbeat.com
(PRAX) Risk Channels and Responsive Allocation - Stock Traders Daily
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history - Yahoo Finance UK
Praxis Precision Medicines announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):